Program to Accelerate Clinical Trials (Alzheimer’s disease)
The Program to Accelerate Clinical Trials from the Alzheimer´s Drug Discovery Foundation provides funding for IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Funding is available to researchers worldwide, at both non-profit research institutions as well as for-profit organizations. Applicants may apply for up to 3 million USD (direct costs only) for multi-year funding support. There are three assessment rounds per year and the next letters of intent are due September 30, 2022 and the full applications are due on December 2, 2022.
Create or log-in to your free account for more functionalities, including a full display of the eligibility criteria such as location and citizenship requirements.